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Abstract
Deltorphins are naturally occurring peptides produced by the skin of the giant monkey frog (Phyllomedusa
bicolor). They are δ-opioid receptor-selective agonists. Herein, we report the design and synthesis of a peptide,
Tyr-d-Ala-(pI)Phe-Glu-Ile-Ile-Gly-NH2 3 (GATE3-8), based on the [d-Ala2]deltorphin II template, which is
δ-selective in in vitro radioligand binding assays over the μ- and κ-opioid receptors. It is a full agonist in
[35S]GTPγS functional assays and analgesic when administered supraspinally to mice. Analgesia of 3
(GATE3-8) is blocked by the selective δ receptor antagonist naltrindole, indicating that the analgesic action of
3 is mediated by the δ-opioid receptor. We have established a radioligand in which 125I is incorporated into 3
(GATE3-8). The radioligand has a KD of 0.1 nM in Chinese hamster ovary (CHO) cells expressing the δ
receptor. Additionally, a series of peptides based on 3 (GATE3-8) was synthesized by incorporating various
halogens in the para position on the aromatic ring of Phe3. The peptides were characterized for binding
affinity at the μ-, δ-, and κ-opioid receptors, which showed a linear correlation between binding affinity and
the size of the halogen substituent. These peptides may be interesting tools for probing δ-opioid receptor
pharmacology.
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ABSTRACT  
Deltorphins are naturally occurring peptides produced by the skin of the giant monkey frog 
(Phyllomedusa bicolor). They are δ-opioid receptor selective agonists. We herein report the 
design and synthesis of a peptide, Tyr-D-Ala-(pI)Phe-Glu-Ile-Ile-Gly-NH2 3 (GATE3-8), based 
on the [DAla
2
]deltorphin II template, which is δ-selective in in vitro radioligand binding assays 
over the µ and κ opioid receptors. It is a full agonist in [
35
S]GTPγS functional assays and 
analgesic when administered supraspinally to mice. Analgesia of 3 (GATE3-8) is blocked by the 
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selective δ receptor antagonist naltrindole, indicating that the analgesia is mediated by the δ 
opioid receptor. We have established a radioligand in which 
125
I is incorporated into 3 (GATE3-
8). The radioligand has a KD of 0.1 nM in Chinese hamster ovary (CHO) cells expressing the δ 
receptor. Additionally, a series of peptides based on 3 (GATE3-8) were synthesized 
incorporating various halogens in the para position on the aromatic ring of Phe
3
. The peptides 
were characterized for binding affinity at the µ-, δ-, and κ-opioid receptors, which showed a 
linear correlation between binding affinity and the size of the halogen substituent. These peptides 
may be interesting tools for probing δ-opioid receptor pharmacology. 
Introduction 
  Opioid analgesics have been used for their pain-relieving properties for centuries. These 
compounds decrease the sensation of pain by binding opioid receptors found in the central and 
peripheral nervous system.
1
 Morphine, the most widely used opioid analgesic, has served as a 
structural template for the design and synthesis of novel opioids. Unfortunately, morphine and its 
clinically used analogs have deleterious side-effects, such as respiratory depression and a high 
potential for addiction. Therefore, it is desirable to design a drug that is able to retain the pain-
relieving properties of morphine without causing dangerous side-effects.
 
 
 Three classes of opioid receptors have been cloned: µ (MOR), δ (DOR), and κ (KOR).  
Subtypes of MOR, DOR, and KOR have also been proposed on the basis of a variety of 
biochemical and pharmacological approaches.
2
 Radiolabeled peptides have been useful in the 
characterization of opioid receptors. Endogenous enkephalin analog probes with tritium such as 
[d-Ala
2
,MePhe
4
,Gly(ol)
5
]enkephalin (DAMGO) and [d-Pen
2
,d-Pen
5
]enkephalin (DPDPE) are 
commercially available MOR and DOR-selective ligands, respectively. However, most tritiated 
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probes have limitations for identifying high affinity binding sites with low expression levels, 
given the specific activity of 28.8 Ci/mmol of tritium.
3
 For example, Zhu et al. could not detect 
binding in brains of DOR knockout mice using [
3
H]DPDPE and [
3
H]deltorphin-II, despite 
findings that both of these compounds retain their analgesic effects when administered 
supraspinally to this mouse.
4
 
Radioiodinated compounds have numerous other clinically and scientifically relevant uses, 
which include tissue ablation, tumor imaging, autoradiography, and binding assays.
5
 High 
specific activity, such as that of 
125
I or 
131
I, has major advantages when visualizing small receptor 
populations. This is illustrated by our recent studies with [
125
I]iodobenzoylnaltrexamide 
([
125
I]IBNtxA). [
125
I]IBNtxA binds with high affinity to the novel opioid target, 6TM/E11.
6
 
Since there are currently no iodinated small molecules or peptides commercially available to 
target DOR, our primary goal was to synthesize a DOR-selective, analgesic opioid peptide 
bearing an iodine atom. The radioiodinated analog could be used for radioligand binding assays 
in rodent brain homogenates, whereas the non-radioactive counterpart could be used as a DOR 
analgesic model compound in rodents, thus creating a useful probe for DOR pharmacology.  
Secretions on the skin of the amphibian Phyllomedusa bicolor, contain opioid peptides such as 
deltorphins, which are highly selective for DOR and analgesic.
7
 In an attempt to synthesize a 
selective radioiodinated probe for DOR we decided to use the DAla
2
-deltorphin II amino acid 
sequence as a template. All peptides synthesized were characterized in radioligand binding 
assays in Chinese hamster ovary (CHO) cell lines stably transfected with opioid receptors. The 
non-radioactive iodinated deltorphin analog, Tyr-DAla-(p-I)Phe-Glu-Ile-Ile-Gly-NH2 3 (GATE3-
8) was further characterized in in vitro [
35
S]GTPγS functional assays and in vivo tail flick 
analgesia assays. The radioiodinated analog, [
125
I]-3, Tyr-DAla-(p-
125
I)Phe-Glu-Ile-Ile-Gly-NH2  
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(
125
I-GATE3-8) was made by the introduction of an amino group at the 4’ position of Phe
3
, 5 and 
followed by a subsequent Sandmeyer reaction.
8
 This radioligand was further characterized in 
saturation binding assays and competition assays confirming its selectivity for DOR. 
Results and Discussion 
Five analogs of DAla
2
-deltorphin II were synthesized using Fmoc-based solid phase peptide 
synthesis.
9
 The Val
5
-Val
6
 of [DAla
2
]Deltorphin II (Table 1) was replaced with Ile
5
- Ile
6 
and pX-
Phe
3
 where X at 4’ position of Phe varied from F, Cl, Br, I to NH2 (Table 1 and Figure 2). 
Valines at positions 5 and 6 were replaced with isoleucine in order to increase hydrophobicity. 
Isoleucine is more branched than valine and increasing the hydrophobicity has been shown to 
increase activity at the δ-receptor.
10
 Additionally the para hydrogen of phenylalanine was 
substituted with various halogens. The atomic radius of each halogen increases with molecular 
weight, resulting in an increase in size of the halogen substituent; F < Cl < Br < I. (Table 2). 
In radioligand binding assays versus [
125
I]BNtxA in opioid transfected CHO membranes, all 
analogs showed selective binding for DOR over MOR, KOR and 6TM/E11 sites. As the size of 
the halogen substituent increased, the affinity of the peptide for DOR increased raising the 
possibility of the peptide forming weak halogen bonds in the protein pocket. There was also no 
significant difference between the affinity of 3 (Ki=0.76 nM) and 4 (Ki= 0.74 nM) compounds 
(Table 3). 3  was further characterized in [
35
S]GTPγS functional assays in DOR transfected CHO 
cells. 3 was a full agonist, similar to the prototypic DOR agonist DPDPE, although it was about 
18-fold less potent (ED50=57nM) than DPDPE (EC50=3nM) and 10-fold less potent than 
deltorphin II (Figure 1a). In in vivo tail flick analgesia assays 3 was as potent (ED50=0.3 ug) as 
DPDPE (ED50=0.4 ug) when given supraspinally (Figure 1b). The analgesia was also 
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antagonized by the DOR selective opioid antagonist naltrindole (NTI), confirming that analgesia 
was exhibited through the activation of DOR (Figure 1c).  
Direct iodination of opioids (tyrosine in position 1 in this case) presents a problem since 
incorporation of iodine usually leads to a loss of affinity. Thereby the precursor to [
125
I]-3, 5, was 
radioiodinated using a modified Sandmeyer reaction (Scheme 1). In saturation binding assays to 
CHO-DOR cell membranes, the KD was 0.1±0.02 nM and the Bmax was 196.97±12.44 fmol/mg 
(Figure 2). We performed competitions assays to validate the site as DOR pharmacologically. 
The prototypic DOR agonists DPDPE (Ki=4.5±0.6 nM) and SNC80 (Ki=9.8±0.7 nM) bound the 
site with high affinity while DOR antagonists such as naltrindole (Ki=0.79±0.16 nM) and 
naltriben (Ki=0.14±0.04 nM) also displayed high affinities consistent with literature values 
(Table 4). We performed competitions assays to validate the site as DOR pharmacologically. The 
prototypic DOR agonists DPDPE (Ki=4.5±0.6 nM) and SNC80 (Ki=9.8±0.7 nM) bound the site 
with high affinity while DOR antagonists such as naltrindole (Ki=0.79±0.16 nM) and naltriben 
(Ki=0.14±0.04 nM) also displayed high affinities consistent with literature values (Table 4).  
 
Conclusions 
We synthesized halogenated analogs of [DAla
2
] Deltorphin II, and all analogs maintained 
selectivity for DOR over MOR and KOR. As the size of the halogen substituent increased, the 
affinity of the peptide for the delta opioid receptor increased. Tyr-DAla-(p-I)Phe-Glu-Ile-Ile-Gly-
NH2 3 , a [DAla
2
] Deltorphin II analog, was found to be highly DOR selective in in vitro 
radioligand binding assays and was a full agonist in [
35
S]GTPγS functional assays. 3  was 
analgesic in mice when given supraspinally. Analgesia was blocked by the selective DOR 
antagonist naltrindole, indicating that the analgesia is mediated by DOR. The peptide 5 was 
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readily radioiodinated using a modified Sandmeyer reaction and bound DOR with high affinity. 
Competition assays confirmed the site is DOR, as prototypical DOR agonists and antagonists 
competed [
125
I]-3 (
125
I-GATE 3-8) with affinities consistent with literature values. Together, our 
findings suggest the compound may be useful to elucidate the molecular mechanisms of DOR-
mediated analgesia in the brain using radioimaging and in vivo behavioral assays. 
Experimental 
Chemistry: 
Peptide Synthesis: Peptide synthesis was performed according to standard Fmoc methodology
11
 
using a Discover SPS microwave system and Accent cleavage system (CEM Corporation, 
Matthews, NC). Fmoc-Gly-CLEAR-Amide Resin was purchased from Peptides International 
(Louisville, KY). The solvents N,N-dimethylformamide (DMF), dicloromethane (DCM), 
acetonitrile, and trifluoroacetic acid (TFA) were purchased from Fisher Scientific (Fair Lawn, 
NJ). The reagents diisopropylcarbodiimide (DIC), phenol and piperidine were purchased from 
Sigma-Aldrich (St. Louis, MO) and Oxyma pure was purchased from Advanced ChemTech 
(Louisville, KY). Amino acids Fmoc-D-Ala-OH·H2O, Fmoc-Glu(OtBu)-OH·H2O, and Fmoc-Ile-
OH were purchased from Peptides International (Louisville, KY). The amino acids Fmoc-
Tyr(tBu)-OH, and Fmoc-Phe(4-Cl)-OH were purchased from Novabiochem (Billerica, MA). The 
amino acid Fmoc-Phe(4-F)-OH was purchased from Advanced ChemTech (Louisville, KY). 
Amino acids Fmoc-(4-Br)-Phe-OH and Fmoc-(4-NHBoc)-Phe-OH were purchased from Chem-
Impex (Wood Dale, IL). The amino acid Fmoc-(4-I)-Phe-OH was purchased from Anaspec 
(Fremont, CA). All reagents were ACS grade or better and used without further purification. 
Synthesis was performed on solid support in a Discover SPS microwave synthesizer. 
Approximately 250mg (0.1mmol) of Fmoc-Gly-CLEAR-Amide Resin was placed in a 50mL 
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fritted plastic reaction vessel and the resin was swelled in 50% DMF and 50% DCM for one 
hour. The initial deprotection was performed with about 6mL of 20% piperidine in DMF for 30 
seconds at 70
o
C followed by 30 seconds at 75
o
C. The resin was washed with DMF and a Kaiser 
test performed to confirm the presence of a primary amine. A 3-fold excess of the first amino 
acid was dissolved in DMF along with a 5-fold excess of Oxyma pure. A 5-fold excess of DIC 
was added to the amino acid mixture and then the entire volume was added to the resin. Coupling 
was performed for five minutes at 75
o
C. Another Kaiser test was then performed to confirm 
completion of the coupling reaction. The deprotection and coupling cycle was repeated as 
necessary until all amino acids were added to the growing peptide chain. After addition of the 
last amino acid, the deprotection was repeated one last time and the resin was washed with 
DCM. Cleavage of the peptide was performed using the Discover SPS microwave in addition to 
the Accent cleavage system. Approximately 6mL of cleavage cocktail (90% TFA/5% water/5% 
phenol) was added to the dried resin and cleavage was performed for 30 minutes at 38
o
C. 
Cleaved peptide was collected by filtration and ether precipitation followed by centrifugation for 
30 minutes at 4
o
C. The peptide was dissolved in water and lyophilized to a powder. HPLC 
analysis revealed crude peptide purity as greater than 95% pure as demonstrated by area under 
the curve. Peptides were analyzed for purity and molecular weight by LC-MS. Purity was greater 
than 95% for all peptides with an M+1 mass spectral analysis within equipment error 
Iodination: 5 was iodinated using a modified Sandmeyer reaction.
8, 12
 18-Crown-6 (303mM) 
and tetrakis copper(I)tetrafluoroborate (254 nM) were dissolved in 40 uL water and incubated 
with 4mCi Na
125
I on ice. A second reaction vial containing 8 mM 5 was incubated with 2 N 
sulfuric acid on ice. 50mM sodium nitrite was added and incubated on ice for 5 minutes. The 
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reaction was quenched with 290 mM sulfamic acid. The reactions were combined and placed on 
ice. Following a 3 hour incubation, the reaction was centrifuged and the supernatant was injected 
onto a reverse-phase HPLC C18 column (Thermo Scientific, 150x4.6mm, 5µm). The gradient 
started at 5% acetonitrile containing 0.1% TFA (1mL/min). During the first 5 min, the gradient 
was increased to 30%, held at 30% for 5 min, increased to 50% during the following 10 min, and 
finally increased to 95% during the final 5 min. The desired product eluted at 15 min and was 
obtained with an unoptimized radiochemical yield of 1.3%. The product was confirmed by 
running 3  as a standard (S1). The yields obtained were lower than expected; we have used the 
Sandmeyer reaction on a different peptide alpha-neoendorphin with yields around ~29% 
8
. 
Efforts are underway to improve the radiochemical yields so this protocol can be used on a 
variety of peptides.   
Pharmacology: 
Receptor-Binding Assays. Competition-binding assays in CHO cells stably expressing MOR, 
DOR, or KOR were performed at 25 °C in potassium phosphate buffer (50 mM; pH 7.4), with 
the inclusion of MgSO4 (5 mM) in the MOR assays. Competition assays were carried out using   
[
125
I]BNtxA
6a
 as described. Specific binding was defined as the difference between total binding 
and nonspecific binding, determined in the presence of levallorphan (8 µM). Protein 
concentration was determined as described by Lowry et al., using bovine serum albumin as the 
standard. Protein concentrations of MOR-CHO, DOR-CHO, and KOR-CHO membranes were 
between 20 and 90 µg/mL, and incubation times were 90 min. [
125
I]3 (
125
I-GATE 3-8) assays 
(0.25mL; 0.045 mg protein) were performed in the presence of a protease inhibitor containing 2 
ug/ml each leupeptin, pepstatin, aprotinin, and bestatin and 0.2mM PMSF. 
Page 8 of 21
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9 
 
6TM/E11 competition binding assays
6b
 using [
125
I]BNtxA (1; 0.15 nM) were carried out in 
whole brain membrane homogenates (0.5 mL; 0.5 mg protein) at 25°C in potassium phosphate 
buffer (50 mM; pH 7.4) with magnesium sulfate (5 mM) for 90 min in the presence of CTAP, 
U50488H, and DPDPE, all at 200 nM, to block traditional opioid binding sites.  
Tail Flick Analgesia Assays.  Male CD-1 mice (25−35 g; Charles River Breeding Laboratories, 
Wilmington, MA) were maintained on a 12 h light/dark cycle with Purina rodent chow and water 
available ad libitum. Mice were housed in groups of five until testing. All animal experiments 
were reviewed and approved by the Institutional Animal Care and Use Committee of Memorial 
Sloan-Kettering Cancer Center. Analgesia was determined using the radiant heat tail flick 
technique
13
 using a machine (Ugo Basile; model 37360). The intensity was set to achieve a 
baseline between 2 and 3 s. The latency to withdraw the tail from a focused light stimulus was 
measured electronically using a photocell. Baseline latencies (2.0−3.0 s) were determined before 
experimental treatments for all animals. Post-treatment tail flick latencies were determined as 
indicated for each experiment, and a maximal latency of 10 s for tail flick was used to minimize 
tissue damage. Naltrindole was given subcutaneously and cumulative dose−response 
experiments carried out with two independent assays with each group (n = 10). 3 (GATE3-8) 
was delivered intracerebroventricularly (i.c.v.) as previously described.
14
 Briefly, the mice were 
anesthetized by isoflurane. A small incision was made, and 3 (2 ul/mouse) was injected using a 
10 uL Hamilton syringe fitted to a 27 gauge needle. Injections were made into the right lateral 
ventricle at the following coordinates: 2 mm caudal to bregma, 2 mm lateral to sagittal suture, 
and 2 mm in depth. Mice were tested for analgesia 15 minutes post injection. The combined 
results are presented as the ED50 with 95% confidence limits (n = 20). Analgesia was defined 
quantally as a doubling, or greater, of the baseline latency. Similar results were obtained 
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analyzing the data in a graded response manner. Analgesic ED50s and confidence limits were 
determined using nonlinear regression analysis Graph Pad Prism (Graphpad Software, La Jolla, 
CA).  
[
35
S]GTPS-Binding Assay: [
35
S]GTPS binding was performed on membranes (60 ug; 1 ml) 
prepared from transfected cells in the presence and absence of the indicated opioid for 60 min at 
30°C in the assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA, and 10 mM 
NaCl) containing 0.05nM [
35
S]GTPS; 2 µg/ml each leupeptin, pepstatin, aprotinin, and bestatin; 
and 30µMGDP, as previously reported.
15
 After the incubation, the reaction was filtered through 
glass-fiber filters (Whatman Schleicher & Schuell, Keene, NH) and washed three times with 3 
ml of ice-cold 50 mM Tris-HCl, pH 7.4, on a semiautomatic cell harvester. Filters were 
transferred into vials with 5 ml of Liquiscent (National Diagnostics, Atlanta, GA), and the 
radioactivity in vials was determined by scintillation spectroscopy in a Tri-Carb 2900TR counter 
(PerkinElmer Life and Analytical Sciences). Basal binding was determined in the presence of 
GDP and the absence of drug. 
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Scheme 1. Radioiodination of 5 to 
125
I-3 (
125
I-GATE3-8) 
 
a)  NaNO2, 2N H2SO4, H3NSO3, 0
ο
C, 5 min b) 18-Crown-6, H2O, Na
125
I, 
Cu(I)(CH3CN)4BF4, 3h 
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Figure 1:  Pharmacology of (Tyr-DAla-(pI)Phe-Glu-Ile-Ile-Gly-NH2) 3 (GATE3-8) 
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a) GTPγS stimulation: Efficacy data were obtained using agonist induced stimulation of 
[
35
S]GTPγS binding assay. Efficacy is represented as EC50 (nM) and percent maximal 
stimulation relative to standard agonist DPDPE (DOR) at 100nM. All values are 
expressed as the mean ± SEM of three separate assays performed in triplicate. 
b) Analgesia: Groups of mice (n=10) received 3 ( i.c.v.) at the indicated doses and were 
tested 15 min later at peak effect to generate the analgesic dose-response curve. ED50 
values (and 95% confidence limits) were 0.3 µg (0.1, 0.47) in CD1 mice by using the 
radiant heat tail-flick assay. 
c) Sensitivity of 3 to opioid antagonists: Groups of mice (n=10) received a fixed dose of 
3(GATE 3-8, 1 ug, i.c.v.) alone or NTI (20 mg/kg, s.c.) given 15 min before 3 . Tail flick 
analgesia was measured 15 min after 3 . Similar results were observed in two 
independent replications. Analgesia of 3  was antagonized  by NTI (ANOVA followed by 
Bonferroni multiple comparison test (p < 0.05)). 
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Figure 2. Saturation curve of [
125
I]-3 (
125
I-GATE3-8) in DOR-CHO membranes 
 
 [
125
I]-3 saturation studies were carried out on DOR-CHO membranes. Results are from a 
representative experiment, and only specific binding is reported. Ratios of total to nonspecific 
binding were 2.5:1.Experiments were replicated at least three times. KD and Bmax were determined 
by nonlinear regression analysis, and the means ± SEM of the replicates were determined. 
The KD value was best fit with a single site, KD = 0.11 ± 0.02 nM, Bmax = 196.97±12.44 fmol/mg. 
Table 1. Sequences of peptides synthesized 
Peptide Name Amino Acid Sequence 
[DAla
2
]Deltorphin II Tyr-DAla-Phe-Glu-Val-Val-Gly-NH2 
1 Tyr-DAla-(pF)Phe-Glu-Ile-Ile-Gly-NH2 
2 Tyr-DAla-(pCl)Phe-Glu-Ile-Ile-Gly-NH2 
3 Tyr-DAla-(pI)Phe-Glu-Ile-Ile-Gly-NH2 
4 Tyr-DAla-(pBr)Phe-Glu-Ile-Ile-Gly-NH2 
5 Tyr-DAla-(pNH2)Phe-Glu-Ile-Ile-Gly-NH2 
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Table 2. HPLC data of Peptides Synthesized; Tyr-DAla-(pX)Phe-Glu-Ile-Ile-Gly-NH2. 
Peptide (pX)Phe HPLC k’ 
(Solvent 1) 
HPLC k’ 
(Solvent 2) 
M+1 
(Calculated) 
Mass Spectral 
Analysis 
(M+1) 
Purity 
1 (pF)Phe 5.20 13.64 828.94 829.93 >98% 
2 (pCl)Phe 5.72 13.86 845.39 844.94 >95% 
3 (pI)Phe 6.65 14.73 936.85 936.36 >95% 
4 (pBr)Phe 5.87 14.24 889.85 890.10 >98% 
5 (pNH2)Phe 3.35 7.99 825.96 825.68 >98% 
HPLC k’= [peptide retention time-solvent retention time]/solvent retention time in Solvent 1 (10-
90% acetonitrile in 0.01% TFA/water over 15 minutes) or Solvent 2 (10-90% methanol in 0.01% 
TFA/water over 15 minutes) with a flow rate of 1.5 mL/min. HPLC analysis was performed 
using a Perkin Elmer HPLC System with a Phenomenex Kinetex C18 column (2.6µm, 
4.6x100mm) at a wavelength of 214nm. Mass spectral analysis took place at CEM Corporation 
(Matthews, NC) using a Thermoscientific LCQ Advantage System with an Atlantis dC18 
analytical column (2.1x150mm). Peptide purity was determined by comparing the area under the 
main peptide peak as compared to other peaks present. 
Table 3. Competition assays against 
125
IBNtxA, Tyr-DAla-(pX)Phe-Glu-Ile-Ile-Gly-NH2. 
Peptide (pX)Phe MOR 
(nM) 
DOR 
(nM) 
KOR 
(nM) 
6TM/E11 
(nM) 
(DAla-2)DeltorphinII  >1000 0.34±0.1 >1000 >1000 
1 (pF)Phe >1000 6±2.47 >1000 >1000 
2 (pCl)Phe >1000 2.44±0.08 >1000 >1000 
3 (pI)Phe >1000 0.76±0.45 >1000 >1000 
4 (pBr)Phe >1000 0.74±0.36 >1000 >1000 
5 (pNH2)Phe >1000 26±4.16 >1000 >1000 
 
Competition studies were performed with the indicated compounds against [
125
I]BNtxA (0.1 nM) 
in membranes from CHO cells stably expressing the indicated cloned opioid receptor or in 
mouse brain membranes for 6TM/E11 sites with blockers to prevent binding to traditional mu, 
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kappa1 and delta receptors as described in the methods section.  Ki values were calculated from 
the IC50 values and represent the means ± SEM of at least three independent replications.  KD’s 
used for calculating Ki‘s were 0.11, 0.03, 0.24 and 0.16 nM for MOR-1, KOR-1, DOR-1 and 
6TM/E11 respectively. 
Table 4. Competition assays against [
125
I]-3 (
125
I-GATE3-8) in DOR-CHO. 
Compound DOR-
CHO 
Ki (nM) 
DPDPE 4.5±0.6 
SNC80 9.8±0.7 
Naltrindole 0.79±0.16 
Naltriben 0.14±0.04 
Competition studies were performed with the indicated compounds against [
125
I]3 (0.2 nM) in 
membranes from CHO cells stably expressing DOR. Ki values were calculated from the IC50 
values
16
 and represent the means ± SEM of at least three independent replications. The KD used 
for calculating Ki’s was 0.1nM. 
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Chinese hamster ovary cells; DPDPE, [D-Pen
2
,D-Pen
5
]Enkephalin; K2CO3, potassium carbonate; 
DMF, N,N-dimethylformamide; DCM, dicloromethane; TFA, trifluoroacetic acid; Tyr, tyrosine; 
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(pNH2)Phe, para-amino-phenylalanine; Glu, glutamic acid; Ile, isoleucine; Gly, glycine; HPLC, 
high pressure liquid chromatography; diisopropylcarbodiimide (DIC) 
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